We don’t usually operate as a news aggregation service here at the Drug and Device Law Blog, but we noticed three items today that we thought would interest many of our readers.
First, today’s Wall Street Journal reports on Pfizer’s unsuccessful (at least before a magistrate judge) effort to subpoena documents about Bextra and Celebrex in the possession of the Journal of the American Medical Association. (HT to FDLI’s SmartBrief.)
Second, today’s New York Times reports that an Alaska court is deciding whether to hold an individual in a psychiatric hospital for 30 days because, among other things, he refuses to take Zyprexa for his mental illness. Since the attorney general’s case against Eli Lilly for alleged off-label promotion of Zyprexa is being tried in the same courthouse, there’s a certain irony there.
Finally, the February issue of Scientific American has this article about the widespread use of antidepressants. We express no opinion about the merits of the article, but it’s out there in the popular press, so many pharmaceutical defense lawyers will be interested in it.